Core Viewpoint - MannKind Corporation has successfully settled the remaining $36.3 million of its 2.50% convertible senior notes, with the settlement completed on March 4, 2026, prior to the maturity date of March 1, 2026 [1] Company Overview - MannKind Corporation is a biopharmaceutical company focused on transforming chronic disease care through innovative, patient-centric solutions [2] - The company specializes in cardiometabolic and orphan lung diseases, developing treatments for serious unmet medical needs such as diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease [2] Product Development Focus - MannKind has deep expertise in drug-device combinations, aiming to deliver therapies that integrate seamlessly into patients' daily lives [3]